Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet, Protein-Restricted | 9 | 2024 | 82 | 3.950 |
Why?
|
| Insulin Resistance | 9 | 2022 | 631 | 3.410 |
Why?
|
| Polycystic Ovary Syndrome | 4 | 2022 | 57 | 2.900 |
Why?
|
| Glucose Intolerance | 5 | 2022 | 73 | 2.640 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2024 | 220 | 1.890 |
Why?
|
| Glucose | 5 | 2023 | 876 | 1.070 |
Why?
|
| Muscle, Skeletal | 5 | 2024 | 922 | 0.970 |
Why?
|
| Hyperandrogenism | 3 | 2022 | 19 | 0.950 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 1199 | 0.880 |
Why?
|
| Ovary | 3 | 2021 | 389 | 0.850 |
Why?
|
| Androgens | 3 | 2022 | 255 | 0.830 |
Why?
|
| Rats | 15 | 2024 | 3645 | 0.830 |
Why?
|
| Rats, Wistar | 6 | 2024 | 356 | 0.790 |
Why?
|
| Reproduction | 1 | 2023 | 234 | 0.770 |
Why?
|
| Endocrinology | 1 | 2023 | 139 | 0.740 |
Why?
|
| Paternal Age | 1 | 2020 | 13 | 0.710 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2017 | 49 | 0.700 |
Why?
|
| Fathers | 1 | 2020 | 66 | 0.680 |
Why?
|
| Fetal Development | 1 | 2021 | 108 | 0.670 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 69 | 0.650 |
Why?
|
| Folic Acid | 2 | 2019 | 290 | 0.630 |
Why?
|
| Oocytes | 4 | 2022 | 291 | 0.620 |
Why?
|
| Pregnancy | 17 | 2024 | 6854 | 0.620 |
Why?
|
| Vitamin B Complex | 2 | 2019 | 41 | 0.620 |
Why?
|
| Insulin | 3 | 2022 | 1188 | 0.610 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2017 | 78 | 0.600 |
Why?
|
| Testosterone | 4 | 2020 | 456 | 0.580 |
Why?
|
| Phenols | 2 | 2015 | 56 | 0.580 |
Why?
|
| Thinness | 1 | 2016 | 67 | 0.510 |
Why?
|
| Animals | 22 | 2024 | 33423 | 0.510 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2826 | 0.500 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2015 | 20 | 0.500 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 17 | 0.490 |
Why?
|
| Estradiol | 2 | 2020 | 534 | 0.480 |
Why?
|
| Signal Transduction | 4 | 2017 | 4499 | 0.480 |
Why?
|
| Endocrine Disruptors | 1 | 2015 | 50 | 0.480 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 63 | 0.480 |
Why?
|
| Insulin-Secreting Cells | 2 | 2015 | 142 | 0.470 |
Why?
|
| Mitochondria | 5 | 2023 | 665 | 0.470 |
Why?
|
| Benzopyrans | 3 | 2013 | 19 | 0.460 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 408 | 0.450 |
Why?
|
| Maternal Exposure | 1 | 2015 | 143 | 0.450 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 789 | 0.450 |
Why?
|
| Receptors, Prostaglandin | 2 | 2013 | 22 | 0.430 |
Why?
|
| Female | 26 | 2024 | 64043 | 0.430 |
Why?
|
| Glucose Tolerance Test | 3 | 2020 | 200 | 0.420 |
Why?
|
| Estrogen Receptor beta | 4 | 2013 | 78 | 0.400 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2012 | 10 | 0.400 |
Why?
|
| Blood Glucose | 2 | 2015 | 1100 | 0.390 |
Why?
|
| Progesterone | 2 | 2012 | 624 | 0.340 |
Why?
|
| Neutrophils | 1 | 2012 | 382 | 0.340 |
Why?
|
| Estrogen Receptor alpha | 4 | 2013 | 444 | 0.330 |
Why?
|
| Adrenomedullin | 2 | 2023 | 74 | 0.320 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 209 | 0.270 |
Why?
|
| Stilbenes | 1 | 2006 | 34 | 0.270 |
Why?
|
| Mitochondrial Dynamics | 2 | 2024 | 46 | 0.270 |
Why?
|
| Hypertension | 1 | 2014 | 1262 | 0.270 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 103 | 0.270 |
Why?
|
| Transcriptional Activation | 2 | 2013 | 483 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1207 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 492 | 0.230 |
Why?
|
| Estrogens | 1 | 2006 | 506 | 0.230 |
Why?
|
| Sex Factors | 2 | 2017 | 1220 | 0.210 |
Why?
|
| Diabetes, Gestational | 1 | 2023 | 97 | 0.190 |
Why?
|
| Cervix Uteri | 2 | 2013 | 69 | 0.190 |
Why?
|
| Labor, Induced | 2 | 2013 | 36 | 0.190 |
Why?
|
| Uterus | 4 | 2012 | 590 | 0.190 |
Why?
|
| Sex Differentiation | 1 | 2021 | 22 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2023 | 259 | 0.180 |
Why?
|
| Mice, Obese | 1 | 2020 | 77 | 0.180 |
Why?
|
| Fasting | 1 | 2022 | 297 | 0.180 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 288 | 0.170 |
Why?
|
| Energy Metabolism | 1 | 2024 | 737 | 0.170 |
Why?
|
| Aneuploidy | 1 | 2020 | 156 | 0.170 |
Why?
|
| Infertility, Female | 1 | 2021 | 165 | 0.170 |
Why?
|
| Obesity | 2 | 2020 | 2083 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2012 | 180 | 0.160 |
Why?
|
| Testis | 1 | 2020 | 407 | 0.160 |
Why?
|
| Humans | 12 | 2023 | 121122 | 0.150 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 67 | 0.150 |
Why?
|
| Male | 8 | 2024 | 58941 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 65 | 0.140 |
Why?
|
| Overweight | 1 | 2020 | 339 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2014 | 84 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2022 | 1451 | 0.130 |
Why?
|
| Testosterone Propionate | 1 | 2015 | 3 | 0.130 |
Why?
|
| Amino Acids | 1 | 2019 | 661 | 0.130 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 27 | 0.130 |
Why?
|
| Hyperinsulinism | 1 | 2015 | 67 | 0.130 |
Why?
|
| Mice | 3 | 2022 | 17406 | 0.130 |
Why?
|
| Flutamide | 1 | 2014 | 24 | 0.120 |
Why?
|
| Estrous Cycle | 1 | 2014 | 31 | 0.120 |
Why?
|
| Mesenteric Arteries | 1 | 2014 | 45 | 0.120 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2014 | 20 | 0.120 |
Why?
|
| Vasoconstriction | 1 | 2014 | 103 | 0.120 |
Why?
|
| Pregnancy, Prolonged | 1 | 2013 | 3 | 0.120 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2013 | 6 | 0.120 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2013 | 4 | 0.120 |
Why?
|
| Cervical Ripening | 1 | 2013 | 7 | 0.120 |
Why?
|
| Uterine Artery | 1 | 2014 | 29 | 0.110 |
Why?
|
| Neuropeptides | 1 | 2014 | 112 | 0.110 |
Why?
|
| Receptors, Progesterone | 2 | 2009 | 866 | 0.110 |
Why?
|
| Ovulation | 1 | 2014 | 112 | 0.110 |
Why?
|
| Models, Animal | 1 | 2016 | 464 | 0.110 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 85 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 54 | 0.110 |
Why?
|
| Angiotensin II | 1 | 2014 | 161 | 0.110 |
Why?
|
| Vasodilation | 1 | 2014 | 191 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2017 | 1612 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 478 | 0.110 |
Why?
|
| Oxygen Consumption | 2 | 2024 | 302 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 447 | 0.110 |
Why?
|
| HL-60 Cells | 1 | 2012 | 31 | 0.100 |
Why?
|
| Pertussis Toxin | 1 | 2012 | 24 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2014 | 1310 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2012 | 700 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 61 | 0.100 |
Why?
|
| Piperidines | 1 | 2013 | 195 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2013 | 281 | 0.100 |
Why?
|
| Weight Gain | 1 | 2014 | 382 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 143 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 522 | 0.090 |
Why?
|
| Age Factors | 1 | 2017 | 2759 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1674 | 0.090 |
Why?
|
| Protein Transport | 1 | 2012 | 369 | 0.090 |
Why?
|
| Ligands | 1 | 2012 | 536 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 873 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 286 | 0.090 |
Why?
|
| Embryo Implantation | 2 | 2008 | 228 | 0.080 |
Why?
|
| Dinoprostone | 1 | 2009 | 76 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2012 | 295 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2008 | 15 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 999 | 0.080 |
Why?
|
| Endometrium | 2 | 2008 | 274 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 3067 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 513 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 2538 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 60 | 0.070 |
Why?
|
| Response Elements | 1 | 2006 | 99 | 0.070 |
Why?
|
| COS Cells | 1 | 2006 | 273 | 0.070 |
Why?
|
| Molecular Structure | 1 | 2006 | 284 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 34 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3402 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4246 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 11690 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 897 | 0.060 |
Why?
|
| Cytochromes b | 1 | 2023 | 5 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 240 | 0.050 |
Why?
|
| Adipocytes | 1 | 2023 | 158 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 1708 | 0.050 |
Why?
|
| Gene Expression | 2 | 2019 | 1577 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2023 | 248 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2476 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 508 | 0.040 |
Why?
|
| Follicular Phase | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cumulus Cells | 1 | 2019 | 43 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 118 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 1292 | 0.040 |
Why?
|
| Kinetics | 1 | 2019 | 1312 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2015 | 46 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2008 | 1099 | 0.030 |
Why?
|
| C-Peptide | 1 | 2015 | 107 | 0.030 |
Why?
|
| Corpus Luteum | 1 | 2014 | 25 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 175 | 0.030 |
Why?
|
| Pancreas | 1 | 2015 | 213 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2014 | 46 | 0.030 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2013 | 10 | 0.030 |
Why?
|
| Furin | 1 | 2013 | 7 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 19 | 0.030 |
Why?
|
| Peptide Hormones | 1 | 2014 | 66 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2014 | 82 | 0.030 |
Why?
|
| Granulosa Cells | 1 | 2014 | 133 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2013 | 6 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2013 | 5 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2013 | 182 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 116 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2013 | 107 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 222 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2013 | 122 | 0.030 |
Why?
|
| Body Weight | 1 | 2015 | 962 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 993 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 343 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 1357 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 3208 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1788 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 371 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1421 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1677 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 5858 | 0.010 |
Why?
|
| Adult | 2 | 2013 | 28389 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 8645 | 0.010 |
Why?
|